You are here: Industry Insights > 2018

News List

AstraZeneca’s drugs with potential in 2018 Shulin Yang
February 12, 2018
The pharmaceutical product sales of AstraZeneca declined by 5% in 2017, to which Onglyza, Symbicort, and Crestor, etc. could be said to have made “big contributions”.
Biotech M&A In 2018: A Tsunami Or A Ripple? forbes
January 23, 2018
Possible biotech M&A targets in 2018 include gene therapy technology and cancer drug makers.
7 Key Cancer Trends For 2018 forbes
January 23, 2018
Here’s a list of major trends and issues that will affect the lives of cancer patients in 2018 -- By Elaine Schattner
The 7 Best Life Science Companies to Work for in 2018 biospace
January 12, 2018
The companies range all over the board, from tech companies to consulting and healthcare to retail. This year’s list was topped by Facebook, but there were seven life science companies on the list.
2 Under-the-Radar Pharma M&A Targets for 2018 biospace
January 12, 2018
Many analysts are looking for a good year for biopharma stocks in 2018. Some of it’s just general optimism at the beginning of the year, but others are pointing to the changes to the tax code that will eventually free up a lot of corporations’ cash.
Avadel Pharmaceuticals Issues 2018 Corporate Outlook biospace
January 02, 2018
Avadel Pharma (NASDAQ:AVDL), “Avadel” or “the Company,” today announced its 2018 corporate objectives and financial expectations, including the commercial launch of Noctiva™ and the anticipated filing of a New Drug Application (NDA) for both FT218
3 FDA topics to watch in 2018 statnews
December 27, 2017
As the year winds down, STAT reporters are taking a look at the stories they’re most eager to track in 2018. Find all our “three to watch” series here.
The 2017 Biotech IPO Winners and Losers biospace
December 26, 2017
Although it was an average year for mergers and acquisitions in the biopharma industry, it was a stronger year for initial public offerings (IPO).

Previous page 1 2 3 4 Next page